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SUMMARY
To estimate the burden of disease due to congenital toxoplasmosis in Sweden the incidence of
primary infections during pregnancy and birth prevalence of congenital toxoplasmosis in 40978
children born in two regions in Sweden was determined. Women possibly infected during
pregnancy were identi®ed based on: 1, detection of speci®c IgG based on neonatal screening of
the phenylketonuria (PKU) card blood spot followed by retrospective testing of stored prenatal
samples to detect women who acquired infection during pregnancy and follow up of their
children to 12 months; 2, detection of speci®c IgM on the PKU blood spot.
The birth prevalence of congenital toxoplasmosis was 0±73}10000 (95% CI
0±15±2±14) (3}40978).
The incidence of primary infection during pregnancy was 5±1}10000 (95% CI 2±6±8±9)
susceptible pregnant women. The seroprevalence in the southern part was 25±7% and in the
Stockholm area 14±0%.
The incidence of infection during pregnancy was low, as the birth prevalence of congenital
toxoplasmosis. Neonatal screening warrants consideration in view of the low cost and
feasibility.
INTRODUCTION
The epidemiology of infection with Toxoplasma gondii
has changed in Sweden since the 1950s. The sero-
prevalence in pregnant women has decreased in the
Stockholm area from around 50% to 14% [1, 2],
same thing is also reported from other parts of Europe
[3±7]. Within Sweden, the prevalence of infection
decreases with latitude, ranging from 26% in the
south of Sweden, similar to Denmark [8], to 12% in
the north in 1987 [9]. Any burden of disease due to
* Author for correspondence.
congenital toxoplasmosis, for example neurological or
visual impairment due to lesions in the brain and}or
retina [10±12] is largely unknown in Sweden. The
number of subsequently veri®ed cases of congenital
toxoplasmosis has been limited to single reports
amongtheapproximately100000childrenbornyearly
in Sweden. However, reported cases do not represent
a true indicator of the real rate as the disease is often
asymptomatic. In addition, data on the risk of
maternal toxoplasmosis are scanty. An incidence of
4±6}1000 pregnancies was found in a small pilot study
from the southern part of Sweden 15 years ago [13]. In122 B. Evenga / rd and others
the Stockholm area in 1987 best estimates of between
0 and 2±7 cases per 1000 pregnancies were obtained by
modelling toxoplasma incidence from seroprevalence
data [7]. Additionally in 1992±3, 4 seroconverters were
found in 3094 pregnant women [2].
The aim of the study was to determine the birth
prevalence and risk of clinical signs, symptoms and
impairment at 1 year of age due to congenital
toxoplasmosis. This would inform rational decisions
about preventive measures.
Studies based on women infected after the ®rst
prenatal blood sample (taken at 10±12 weeks of
gestation) have shown that neonatal detection of IgM
on blood spots is 70±80% sensitive [14]. However,
sensitivity may be lower for babies born to women
infected in the ®rst trimester of pregnancy. We
therefore also attempted to identify all women who
were possibly infected during pregnancy, in addition
to identifying children by neonatal screening. We
followed up all children to determine congenital
infection status.
POPULATION AND METHODS
After delivery, all mothers of children born in
Stockholm County between 1 April 1997 and 31 July
1998 and in Ska / ne County between 1 May 1997 and
31 July 1998 received written information about the
study and consent to participation was sought. If the
mother declined this was marked on the phenyl-
ketonuria card, (PKU card). Blood spots were
collected on ®lter paper cards between days 3±5 after
birth, as part of the routine screening for inborn error
of metabolism (e.g. phenylketonuria) and congenital
hypothyroidism.
Screening for mothers infected during pregnancy and
follow up of their children
Mothers with previous toxoplasma infection were
identi®ed by analysis of the eluates from blood spots
on PKU cards for toxoplasma IgG antibody activity.
To identify women infected during pregnancy,
stored prepartum samples obtained in week 12 (mean,
SD 4±61 weeks) from the seropositive mothers were
tested for speci®c IgG and IgM.
The following de®nitions were used:
(a) de®nitive infection, seroconversion ± a change
from undetectable anti-toxoplasma IgG antibodies in
thesampledrawnduringearlypregnancytodetectable
IgG antibodies after birth; (b) possibly infected;
IgG level "100 IU or demonstrable IgM and an IgG
avidity index !30.
To con®rm serological results, women possibly
infected during pregnancy and their children were
sampledforcon®rmatoryserologicalanalyses(speci®c
IgM}A and IgG tests)
All children born to women who were possibly
infected during pregnancy were followed clinically
and serologically for 12 months.
Clinical, neurological and ophthalmological assess-
ments and evaluation of developmental milestones
were performed at 1, 3, 6, 9, and 12 months. A cranial
ultrasound investigation was performed at the ®rst
visit and, in children with con®rmed congenital
toxoplasmosis,computerizedtomographyofthe brain
was also performed. A psychometric evaluation using
the Griﬃth developmental scale [15] was performed
between 12 and 15 months of age.
The ophthalmological investigations depended on
the age of the patients and included external investi-
gation of major ocular malformations, visual acuity
assessment with the preferential looking technique,
evaluation of ocular motility, cover for the detection
of strabismus, evaluation of pupillary reactions to
light and indirect ophthalmology monocularly and}or
binocularly for the detection of signs of chorioretinitis
in the fundi. A hearing assessment was routinely
performed at the health care centre at 8 months of
age.
Antibody levels were measured between 3 weeks
and 3 months, and repeated at 3, 6, 9 and 12 months
of age.
The criteria for serodiagnosis of possible toxo-
plasma infection during pregnancy were based on the
de®nitions of a European Union Concerted Action on
Congenital Toxoplasmosis [16] modi®ed by the ad-
dition of avidity test [17, 18]. To certify correct
identity of samples from the mothers and to exclude
other potential hazardous infections, pregnancy sera
were tested in parallel against TORCH (toxoplasma,
rubella, CMV, herpes simplex virus type common and
type 2) antigens.
Neonatal screening
Infected children were identi®ed by detection of
toxoplasma IgM in eluates from PKU-cards. If IgM
was positive further serum samples were taken from123 Screening for congenital toxoplasmosis
the child and mother for con®rmatory analyses of
IgM}IgA. Children with serological markers for
toxoplasma infection were followed clinically and
serologically to 12 months of age in the same way as
the children born to possibly infected mothers.
The criterion for diagnosis of congenital toxo-
plasmosis was the presence of speci®c IgG at 12
months of age.
Laboratory assays
Eluates from PKU ®lter paper cards (Schleicher &
Schull no 903, Dassel, Germany): disks were cut out
from the PKU cards (diameter 3±2 mm) and analysed
for speci®c IgM antibodies (FEIA, Labsystem, Hel-
sinki) as described [19] and for speci®c IgG antibodies
[20] (EIA, Labsystem, Helsinki).
Maternal sera were analysed for speci®c antibodies
using an automated ELISA (Toxo IgM, Toxo IgG,
Abbotts Diagnostics). Sera from the children were
analysed for speci®c IgM and IgG using the same
assays and for speci®c IgM and IgA also ISAGA
PLUS IgA}IgM test (Bio-Merieux). Avidity of the
IgG antibodies was measured using a commercial
assay (Labsystem, Helsinki). The interpretation of the
avidity results was according to the manufacturer
recommendations: index " 30% excludes a primary
infection within 3 months; an index ! 15% is
compatible with an acute infection; 15±30% is an
intermediatevaluethatmayindicateprimaryinfection
during the last 6 months.
PCR for detection of Toxoplasma gondii DNA,
usinganestedtechnique,wasperformedinallchildren
born to women with suspected infection during
pregnancy using EDTA-blood from the newborn. The
DNA was prepared from leucocyte suspension, con-
taining approximately 500 ll lysed EDTA-blood, with
the Qiagen Amp Kit (Qiagen, Stockholm, Sweden)
and eluted in 100 llH #O. 20 ll of the puri®ed DNA
were then T. gondii B1 gene ampli®ed with a nested
PCR method [21] slightly modi®ed from Burg [22].
The nested PCR fragments were separated by
ethidium bromide stained agarose gel (4%) electro-
phoresis and compared to a standard DNA molecular
size ladder (100 bp).
The diagnosis of congenital toxoplasmosis was
®nally established at 12 months of age if the child still
had speci®c IgG antibodies.
This study was approved by the ethical committee
at the Karolinska Institutet.
RESULTS
Eluates from 40978 new-borns were analysed; 26885
were from the Stockholm area (65±6%) and 14093
from Ska / ne (34±4%), representing 97±1% of all
newborns during the study period.
Screening for mothers infected during pregnancy and
follow up of their children
Speci®c IgG was found in 3772 cards in Stockholm
and 3618 cards in Ska / ne, giving a seroprevalence of
14±0% in the Stockholm area and 25±7% in Ska / ne.
The results are shown in detail in Figure 1.
In total, 7390 pregnancy sera were requested of
mothers with IgG positive children. Of these 30%
could not be retrieved due to a health service
reorganisation in Ska / ne. Thus 33589 women were
susceptible to toxoplasma infection (i.e. speci®c IgG
negative).
Seroconversion was detected in 12 women. At
follow up 3 of the 12 children born to these women
had evidence of congenital infection based on speci®c
IgM and IgA antibodies in con®rmatory neonatal
serum and persistence of IgG at the age of 12 months.
IgG seroconversion but no other serological
markers for toxoplasma infection was found in a
further six mothers. These sera were, however, not
considered further as the antibody pro®les in TORCH
analysis indicated they had been mislabelled. Children
of these six mothers were anyway followed to 12
months but none had any clinical or serological
evidence of congenital infection.
TheincidenceofprimaryinfectionwithToxoplasma
gondii (de®ned as seroconversion during pregnancy in
women giving birth to live children) was 0±51 per 1000
susceptible pregnancies (9 months) (95%CI ¯
0±26±0±89; based on the Poisson distribution). The
overall risk of mother to child transmission was
3}12¯25%.
Another 31 children were enrolled in the follow-up
studyduetosuspicionofinfectionbetweenconception
and the ®rst prenatal sample. Of these 3 were lost to
follow-up either due to parental refusal (1), refusal of
paediatrician (1) or emigration (1). None of the
children lost to follow-up had demonstrable IgM
antibodies in the PKU card eluates or clinical signs of
toxoplasma infection. All 28 children followed for 12
months became seronegative, thus excluding a con-
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Fig. 2. Toxoplasma IgM screening of newborns.
Neonatal screening
Fourteen children were IgM positive on PKU card
screening (Fig. 2). Three of these had congenital
infection con®rmed at 1 year, and one preterm child
died without clinical signs or post mortem ®ndings of
congenital toxoplasmosis. In the remaining 10 chil-
dren the diagnosis of congenital toxoplasmosis was
excluded. In 8 of these 10 children neonatal investi-
gation including serum sampling from the child and
the mother was required. Con®rmatory analyses were
negative and further follow up was not indicated. Due
to high levels of IgG antibodies in the newborn and
the mother, two children were followed until 1 year of
age but were not treated.
All three children with congenital toxoplasmosis
were born to mothers who had seroconverted during
pregnancy and who were identi®ed by the retro-
spective testing of stored prenatal samples. They were
born in gestational week 39 or 40 and received
treatment for 1 year [23]. Two of these children had
clinical signs of the infection: one had hydrocephalus,
intracranial calci®cations, a small corneal diameter
and chorioretinitis in the right eye; the other had
intracranial calci®cations [24]. The most severely
aﬀected child had a demonstrable toxoplasma DNA
in EDTA-blood and speci®c IgG remained at a high
level after completion of treatment.
The birth prevalence of congenital toxoplasmosis in
liveborn children was 3}40978 equivalent to 0±73}
10000 (95% CI 0±15±2±14).
DISCUSSION
The prevalence of susceptibility to toxoplasma
infection in pregnant women was higher than reported
in 1982±3. In the southern part of Sweden (Ska / ne) the
seroprevalence fell from 40% to 25±7% and is now125 Screening for congenital toxoplasmosis
very similar to neighbouring Denmark (27±6%) [14].
As previously reported, the prevalence of sero-
positivity to toxoplasma infection decreased with
latitude, being 14±0% in the Stockholm area. The
incidence of infection in susceptible women was
0±51}1000 (95% CI 0±35±1±18) calculated as sero-
conversions per 1000 pregnancies in susceptible
women. Comparison of this ®gure with other coun-
tries is diﬃcult as few studies take account of the time
period between the negative and positive test when
reporting incidence [6]. Recent estimates of the
incidence}1000 susceptible pregnancies are 2±9
(2±48±3±45) in Denmark [14], 0±82 (0±48±1±32) in
Norway (based on 11 seroconversions) [25], and 3±4
(2±23±4±86) in Finland [26]. The incidence is similar for
Sweden and Norway but signi®cantly higher in
Finland and Denmark. These diﬀerences may re¯ect
the use of diﬀerent tests and diﬀerent cut-oﬀs for test
positivity, or genuine regional diﬀerences in exposure.
The birth prevalence of congenital toxoplasmosis in
this Swedish study is 0±73}10000 but with wide
con®dence intervals (95% CI 0±15±2±14). The birth
prevalence of congenital toxoplasmosis per 10000 live
births reported elsewhere in Scandinavia is 3±0 (95%
CI1±98±4±37)inDenmark[14],3±3inNorway(95%CI
1±63±5±83) [25], and 2±4 (95% CI 0±7±6±1) in Finland
[26]. Although all these studies were performed during
a reasonably close time period (Denmark 1992±6,
Norway 1992±4, Finland 1988±9), there is a signi®cant
diﬀerence between the birth prevalence observed in
Sweden compared with Denmark (P¯0±01) and
Norway (P¯0±15) but not Finland (P¯0±11) (2
sided Fisher's exact test). There may truly be a lower
prevalence in Sweden possibly due to diﬀerent dietary
habits and}or latitude. A similar ®gure to Sweden was
reported from New England. This was 0±82}10000
births (95% CI; 0±61±1±07) [27]. Conversely, a recent
report from Poznan (Polen), gave a birth prevalence
of 4±72}10000 births (2±51±8±08) [28].
False positive results in screening tests results add
to the anxiety of parents and to costs and the
requirements for speci®city are very high. In the
present investigation, a setting of a study, the positive
predictive value of screening for seroconversion was
6% (12}210 see Fig. 1). In other words, for every 100
women requiring further testing, only 6 truly sero-
converted. This ®gure underestimates the number
unnecessarily requiring further testing as we did not
undertake retrospective testing of stored samples in
mother±child pairs with undetectable IgG on the
PKU card. The positive predictive value of a positive
neonatal IgM result on PKU card (Fig. 2) was
reasonable (3}14, 21%). In our study 11 false positive
reactions occurred (0±25}1000). In the majority of
cases, serological follow up of the mother and child
resolved the diagnostic situation, minimizing the need
for unnecessary follow up of the child. Similar results
for the positive predictive value of neonatal IgM
screening have been reported from other programmes
[14, 28]. Previous studies have found an IgM sero-
prevalence of 50±77% in neonates with congenital
toxoplasmosis [29, 30]. In particular, children infected
early in pregnancy may have no detectable toxo-
plasma speci®c IgM at birth [29]. However, the
opportunity for longer treatment of toxoplasma in
pregnancy may shorten the duration of IgM response
in the fetus. Few data are available on non-treated
mother±child pairs. Our data adds only marginal
information on the sensitivity of neonatal screening
for IgM on PKU cards compared with detection of
maternal infection during pregnancy and follow up of
the children to 12 months. This is due to the very low
prevalence of congenital toxoplasmosis: no more
cases were added from the retrospective testing of
prenatal samples or reported from the diagnostic
laboratories. The low incidence of primary maternal
infection in the Swedish pregnant population, means
that the uncertain bene®t of prenatal screening to a
small number of women and children would not
outweigh the risk of side eﬀects from invasive
diagnosis and treatment and the high cost. However,
neonatal screening is clearly feasible and practical.
The cost of a neonatal screening based on detection of
speci®c IgM islow, compared to the expenses involved
forcaringforoneseverelydamagedchild.Thenumber
of parent falsely alerted for every true case found is
minimal.
Neonatal screening has been applied for a decade in
the New England area, USA [27] with a similar
prevalence of congenital toxoplasmosis to Sweden
and was started in 1999 in Denmark. The eﬀectiveness
of postnatal treatment in asymptomatic children is
not established but is widely believed to be justi®ed
[27, 31, 32]. Our results will form the basis for
consideration of a Swedish policy on neonatal
screening.
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